Referred to the House Committee on Energy and Commerce.
This bill amends 21 U.S.C. 352(f) to allow required labeling for medical devices, including in vitro diagnostics, to be provided solely by electronic means. It requires electronic labeling to be readily accessible, obliges manufacturers to provide a free paper copy upon request, and permits the Secretary of HHS to issue orders adding or excepting labeling requirements for device types.
Progressives emphasize equity and access; conservatives emphasize deregulation and cost savings.
Narrow, industry-friendly administrative change with consumer protections likely attracts bipartisan support.
This bill amends 21 U.S.C. 352(f) to allow required labeling for medical devices, including in vitro diagnostics, to be provided solely by electronic means.
It requires electronic labeling to be readily accessible, obliges manufacturers to provide a free paper copy upon request, and permits the Secretary of HHS to issue orders adding or excepting labeling requirements for device types.
The Secretary must publish proposed and final orders in the Federal Register and may require on-device label content only if necessary to assure device safety and effectiveness.
Small, technical regulatory reform with limited fiscal impact and built-in safeguards increases prospects, though stakeholder and procedural issues remain.
How solid the drafting looks.
Progressives emphasize equity and access; conservatives emphasize deregulation and cost savings.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize equity and access; conservatives emphasize deregulation and cost savings.
Cautious acceptance of modernization paired with concern for equity and safety.
Support hinges on strong safeguards ensuring access for underserved populations and clear limits on replacing in-person warnings.
Pragmatic support for updating labeling rules if implemented with clear, enforceable safeguards.
Appreciates built-in paper-request option and Secretary oversight but wants definitional clarity and predictable procedures.
Generally favorable as a deregulatory, cost-reducing modernization measure.
Sees electronic labeling as flexibly reducing burdens while preserving manufacturer discretion and Secretary oversight limited to safety needs.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Small, technical regulatory reform with limited fiscal impact and built-in safeguards increases prospects, though stakeholder and procedural issues remain.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize equity and access; conservatives emphasize deregulation and cost savings.
Small, technical regulatory reform with limited fiscal impact and built-in safeguards increases prospects, though stakeholder and procedura…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Medical Device Electronic Labeling Act.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.